Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

RxSight (RXST) Accumulated Depreciation & Amortization (2020 - 2025)

RxSight filings provide 6 years of Accumulated Depreciation & Amortization readings, the most recent being $3.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 8.33% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 8.33% decrease, with the full-year FY2025 number at $3.3 million, down 8.33% from a year prior.
  • Accumulated Depreciation & Amortization hit $3.3 million in Q4 2025 for RxSight, down from $3.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.1 million in Q4 2023 to a low of $3.3 million in Q4 2025.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $3.9 million (2022), compared with a mean of $3.8 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 5.13% in 2023 and later dropped 12.2% in 2024.
  • RxSight's Accumulated Depreciation & Amortization stood at $4.0 million in 2021, then fell by 2.5% to $3.9 million in 2022, then increased by 5.13% to $4.1 million in 2023, then fell by 12.2% to $3.6 million in 2024, then decreased by 8.33% to $3.3 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $3.3 million (Q4 2025), $3.6 million (Q4 2024), and $4.1 million (Q4 2023) per Business Quant data.